Astrazeneca paves the way to develop AI GP
AstraZeneca outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC after limited lung cancer showing.
AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to differentiate the antibody-drug conjugate (ADC) from competitors while offering an explanation why the TROP2-directed therapy appears to work only in some non-small cell lung cancer (NSCLC) patients.
What this means for you is, although algorithms have been used in data by the NHS for decades, this has opened a new path for AI tech which as it it developed will become more intuitive. And in the event of a pandemic will be used to cattle people to the ‘right treatment’ using indicators generated by AI, not by a GP.
You can see this developing into a screening process for GP surgeries and as the NHS is crying out for more help, you can see the health industry ( big pharma) rolling a pat out ot this in the near future.
